Keyphrases
Chronic Lymphocytic Leukemia
97%
Type 2 Diabetes Mellitus (T2DM)
40%
Targeted Treatment
30%
Overall Survival
25%
Population-based Cohort
23%
Leukemia Patients
21%
Clinical Care
20%
Bile Duct Cancer
20%
Clinical Research
20%
Atrial Fibrillation
20%
Comorbidity Index
20%
Interleukin-6
20%
Pancreatic Cancer
20%
Machine Learning
20%
Systematic Literature Review
20%
Colorectal Cancer
20%
High Risk
20%
Real-world Outcomes
20%
Second-line Treatment
20%
Cause of Death
20%
Confidence Interval
20%
Causes of Mortality
20%
Risk Factors
15%
Gastrointestinal Cancer
15%
Rituximab
13%
Bendamustine
10%
Fludarabine
10%
Cyclophosphamide
10%
Treatment-free Survival
10%
Time-to-treatment
8%
Delayed Diagnosis
7%
Event-free Survival
7%
Ibrutinib
6%
Treatment Initiation
6%
Treatment Type
6%
Targeted Drugs
6%
Survival Events
5%
Interleukin-6 Levels
5%
Clinical Application
5%
Therapeutic Target
5%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Lymphatic Leukemia
60%
Overall Survival
21%
Bile Duct Cancer
20%
Biological Marker
20%
Colorectal Cancer
20%
Cause of Death
20%
Atrial Fibrillation
20%
Non Insulin Dependent Diabetes Mellitus
20%
Pancreas Cancer
20%
Interleukin 6
20%
Rituximab
16%
Malignant Neoplasm
15%
Digestive System Cancer
12%
Fludarabine
12%
Cyclophosphamide
12%
Bendamustine
12%
Ibrutinib
7%
Prevalence
6%
Infection
5%
Medicine and Dentistry
B-Cell Chronic Lymphocytic Leukemia
100%
Maturity Onset Diabetes of the Young
40%
Overall Survival
23%
Atrial Fibrillation
20%
Chronic Lymphocytic Leukemia
20%
Cause of Death
20%
Rituximab
16%
Targeted Therapy
12%
Bendamustine
12%
Fludarabine
12%
Cyclophosphamide
12%
Infection
10%
Prevalence
9%
Event Free Survival
8%
Ibrutinib
7%
